Reimbursement failures are rarely the result of poor billing alone. More often, they stem from misalignment between scientific decisions, coverage policy, market access strategy, and operational execution. Laboratories invest heavily in high-quality science and advanced diagnostics, yet those investments frequently fail to translate into payment due to disconnects that occur long before a claim is submitted.

In this interview-style executive session, Abby Wright, Founder & CEO of PHAZE 4 Medical, a Fractional Market Access Firm, and Sarah Stewart, Vice President of TELCOR Revenue Cycle Services, explore how reimbursement breaks down for otherwise sound science and how labs can correct course. The discussion will examine how early decisions in test design, clinical evidence development, documentation standards, and internal policy creation directly influence payer behavior, cash flow, and collections.

Attendees will gain insight into why billing teams and systems are often unfairly blamed for reimbursement challenges that originate upstream, and how tighter alignment between market access, scientific leadership, and billing is essential for sustainable reimbursement success. The session will provide practical, cross-functional strategies for building flexible reimbursement policies that protect scientific integrity, support payer expectations, and reduce revenue leakage without compromising patient care.

By the end of this session, attendees will be able to:

• Identify where reimbursement commonly breaks down despite strong clinical science.
• Understand how scientific, market access, financial, and operational decisions collectively impact collections.
• Recognize why misalignment between Market Access and Billing leaves revenue on the table.
• Apply practical strategies to better align test design, documentation, and payer requirements.
• Build flexible reimbursement policies that support sustainable revenue while preserving scientific rigor.